Article

Novel Hormone Therapy Combination Shown to Prolong Survival

A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

A phase 3 randomized trial of two hormone therapies, anastrozole and Faslodex (fulvestrant), showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

Both are approved for women with hormone-positive metastatic breast cancer. Faslodex is used when the cancer has stopped responding to other hormonal therapies. Anastrozole is an aromatase inhibitor also approved to prevent breast cancer from recurring in women with early-stage disease.

The trial, which was presented a breast cancer conference in December, included 707 women who had not been previously treated for metastatic cancer. The combination improved median survival from 41.3 months to 47.7 months.

Related Videos
Image of woman with blonde hair.
Image of woman with brown hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a woman wearing a red tank top.
Image of Annie Bond.
Image of a man with rectangular glasses and short dark hair.
Image of a woman with long dark hair.
Related Content